Search

Author/Creator Petrylak, D P

1. 223TiPEV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma. (24th November 2019)

Authors:
Petrylak, D P; Rosenberg, J E; Lee, J; Yonese, J; Duran, I; Loriot, Y; Sonpavde, G; Wu, C; Gartner, E M; Melhem-Bertrandt, A; Powles, T
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 842PCTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC). (23rd October 2018)

Authors:
Morris, M J; Vogelzang, N J; Sartor, O; Armour, A; Messmann, R; Groaning, M; Robarts, A; Tolcher, A W; Gordon, M; Babiker, H M; Kuo, P; Kearney, M; Jendrisak, A; Wang, Y; Landers, M; Petrylak, D P
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 853PARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups. (1st October 2019)

Authors:
Stenzl, A; Szmulewitz, R Z; Petrylak, D P; Holzbeierlein, J; Villers, A; Azad, A A; Alcaraz, A; Alekseev, B Y; Iguchi, T; Shore, N D; Rosbrook, B; Baron, B; Haas, G P; Morlock, R; Ramaswamy, K; Armstrong, A J
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 865PDRANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results. (23rd October 2018)

Authors:
Petrylak, D P; Sternberg, C N; Drakaki, A; de Wit, R; Nishiyama, H; Necchi, A; Castellano, D; Bamias, A; Chi, K N; van der Heijden, M S; Matsubara, N; Hussain, S; Flechon, A; Alekseev, B Y; Yu, E Y; Walgren, R A; Russo, F; Zimmermann, A H; Bell-Mcguinn, K M; Powles, T B
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. 922TiPEV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC). (23rd October 2018)

Authors:
Petrylak, D P; Rosenberg, J; Duran, I; Loriot, Y; Sonpavde, G; Wu, C; Gartner, E; Melhem-Bertrandt, A; Powles, T
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. (3rd May 2019)

Authors:
Fradet, Y; Bellmunt, J; Vaughn, D J; Lee, J L; Fong, L; Vogelzang, N J; Climent, M A; Petrylak, D P; Choueiri, T K; Necchi, A; Gerritsen, W; Gurney, H; Quinn, D I; Culine, S; Sternberg, C N; Nam, K; Frenkl, T L; Perini, R F; de Wit, R; Bajorin, D F
Journal:
Annals of oncology
Issue:
Volume 30:Number 6(2019)
Page Start:
970
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗